Exclusive: GSK CEO Emma Walmsley talks about vaccines, M&A and the company’s future
British drug giant GSK is at an inflection point. The company shed its consumer unit Haleon and plans to put the proceeds into building out its pipeline. It just had an RSV vaccine approved, and it’s done a $2 billion deal for Bellus Health and its chronic cough medicine.
Endpoints News‘ Drew Armstrong sat down with Walmsley in Cambridge, MA, to talk about the company’s strategy over the next several years, how it’ll sell down and spend its remaining stake in Haleon and the importance of vaccines to the company’s future.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.